The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase IB trial of 5-azacitidine (5AC) and suberoylanilide hydroxamic acid (SAHA) in patients with metastatic or locally recurrent nasopharyngeal carcinoma (NPC) and NK-T cell lymphoma.
Wen Son Hsieh
No relevant relationships to disclose
Eng Huat Tan
No relevant relationships to disclose
Wan-Teck Lim
No relevant relationships to disclose
Ross A. Soo
No relevant relationships to disclose
Anthony T. C. Chan
No relevant relationships to disclose
Edwin P. Hui
No relevant relationships to disclose
Soo-Chin Lee
No relevant relationships to disclose
John Soon Wah Low
No relevant relationships to disclose
Pei Li Lim
No relevant relationships to disclose
Thomas Kwok Seng Loh
No relevant relationships to disclose
Matthew M. Ames
No relevant relationships to disclose
Joel M. Reid
No relevant relationships to disclose
Paul Gerard Murray
No relevant relationships to disclose
Qian Tao
No relevant relationships to disclose
Boon C. Goh
No relevant relationships to disclose
Richard F. Ambinder
No relevant relationships to disclose